These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30847174)

  • 1. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.
    Nahleh Z; Botrus G; Dwivedi A; Jennings M; Nagy S; Tfayli A
    Mol Clin Oncol; 2019 Mar; 10(3):357-365. PubMed ID: 30847174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials.
    Wei J; Luo Y; Fu D
    Onco Targets Ther; 2018; 11():9049-9059. PubMed ID: 30588017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    Sun Z; Lan X; Xu S; Li S; Xi Y
    BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
    Han R; Wang G; Zhang Y; Zhao X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
    Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Abraham J; Thomas J; Provenzano E; Hughes-Davies L; Gounaris I; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Bartlett J; Caldas C; Cameron DA; Hayward L;
    Lancet Oncol; 2015 Jun; 16(6):656-66. PubMed ID: 25975632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
    Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham JE; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Rea D; Caldas C; Bartlett JMS; Cameron DA; Provenzano E; Thomas J; Hayward RL;
    Ann Oncol; 2017 Aug; 28(8):1817-1824. PubMed ID: 28459938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.
    Lindholm EM; Ragle Aure M; Haugen MH; Kleivi Sahlberg K; Kristensen VN; Nebdal D; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Mol Oncol; 2019 Oct; 13(10):2278-2296. PubMed ID: 31402562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
    Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
    Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
    JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
    Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
    PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
    Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
    Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials.
    Li C; Xiang A; Chen X; Yin K; Lu J; Yin W
    Onco Targets Ther; 2017; 10():3155-3168. PubMed ID: 28721065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis.
    Wang BC; Fu C; Xie LK; Kuang BH; Zhao YX
    Ann Pharmacother; 2020 Jun; 54(6):517-525. PubMed ID: 31855061
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
    Brodowicz T; Lang I; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Petruzelka L; Eniu A; Anghel R; Koynov K; Vrbanec D; Pienkowski T; Melichar B; Spanik S; Ahlers S; Messinger D; Inbar MJ; Zielinski C
    Br J Cancer; 2014 Nov; 111(11):2051-7. PubMed ID: 25268370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.